The puzzling duality of mesenchymal stem cells and adipocytes in bone marrow and ageing.
Gonzalez-Garcia B., Aparicio C., Abia R., Muriana FJG., Jaramillo-Carmona SM.
Narrative Review, published in NPJ Aging (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- NPJ Aging (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41851121
- DOI
- 10.1038/s41514-026-00353-1
Abstract (original English)
Mesenchymal stem cells (MSCs) in bone marrow (BM) play a role in the development of BM adipose tissue (BMAT). Here, we propose ways to restock the BM-MSC niche to meet the needs of BMAT in ageing, including the activation of pluripotent precursor cells, the breakdown of BM-MSC grafts and the mobilisation of extramedullary MSCs. It can be exploited to understand the BM-MSC-adipocyte axis in ageing and better target anti-ageing interventions.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.